Niaid covid-19 ACTIV3
Active Awarded Last action
- Contract number
- 75N91020F00039
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $159,121,570
Award facts
- Contract value 100% obligated
- $159,121,570.00 Current and potential, with all options
- Completion date 95% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$74,466,450 | |
| Other Administrative Action | -$1,080,477 | |
| Other Administrative Action | $1,999,291 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | -$20,576,810 | |
| Other Administrative Action | $35,724,062 | |
| Other Administrative Action | -$7,368,816 | |
| Supplemental Agreement for work within scope | $26,150,457 | |
| Original award | $198,740,313 |
Show all 12
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 2, 2020, under the NIAID master indefinite delivery contract HHSN261201500003I for COVID-19 ACTIV3 research and development work, with a ceiling value of $159.1 million.
Place of performance is Frederick, MD. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of February 28, 2027.
Service Contract Inventory reporting for this order captures government-invoiced labor across fiscal years 2021–2025. FY2025 activity (the most recent reported year) reflects 39.4 FTEs and 82,034 contractor hours, with a derived government-paid hourly rate of $316.66/hr. The derived rate has trended upward across the reported period, rising from $183.42/hr in FY2021 to $666.92/hr in FY2022, moderating to $274.11/hr in FY2023, then rising again to $371.29/hr in FY2024. In FY2025, subcontractors accounted for 84% of contractor hours, with three subcontractors reported. Total invoiced labor across the order's five reported fiscal years (FY2021–FY2025) was $153.7 million, with FY2022 representing the peak at $57.8 million and FY2024 the trough at $20.8 million.
Quick answers
Who was awarded contract 75N91020F00039?
75N91020F00039 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 2, 2020.
How much is contract 75N91020F00039 worth?
The government has obligated $159,121,570 on 75N91020F00039.
Which agency awarded contract 75N91020F00039?
National Cancer Institute (National Institutes of Health) awarded 75N91020F00039, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91020F00039 an order under another contract?
Yes. 75N91020F00039 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00039 competed?
The extent of competition for 75N91020F00039 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award